FI69639C - Preparat foer anvaendning vid klamydia-diagnostik - Google Patents
Preparat foer anvaendning vid klamydia-diagnostik Download PDFInfo
- Publication number
- FI69639C FI69639C FI822348A FI822348A FI69639C FI 69639 C FI69639 C FI 69639C FI 822348 A FI822348 A FI 822348A FI 822348 A FI822348 A FI 822348A FI 69639 C FI69639 C FI 69639C
- Authority
- FI
- Finland
- Prior art keywords
- chlamydia
- lipopolysaccharide
- group
- kdo
- mutants
- Prior art date
Links
- 239000002158 endotoxin Substances 0.000 claims abstract description 85
- 229920006008 lipopolysaccharide Polymers 0.000 claims abstract description 83
- 241000894006 Bacteria Species 0.000 claims abstract description 32
- 238000002360 preparation method Methods 0.000 claims abstract description 29
- 239000000427 antigen Substances 0.000 claims abstract description 22
- 108091007433 antigens Proteins 0.000 claims abstract description 22
- 102000036639 antigens Human genes 0.000 claims abstract description 22
- 229930186217 Glycolipid Natural products 0.000 claims abstract description 18
- 238000004519 manufacturing process Methods 0.000 claims abstract description 8
- 241000606161 Chlamydia Species 0.000 claims description 48
- HVCOBJNICQPDBP-UHFFFAOYSA-N 3-[3-[3,5-dihydroxy-6-methyl-4-(3,4,5-trihydroxy-6-methyloxan-2-yl)oxyoxan-2-yl]oxydecanoyloxy]decanoic acid;hydrate Chemical compound O.OC1C(OC(CC(=O)OC(CCCCCCC)CC(O)=O)CCCCCCC)OC(C)C(O)C1OC1C(O)C(O)C(O)C(C)O1 HVCOBJNICQPDBP-UHFFFAOYSA-N 0.000 claims description 16
- 229920001542 oligosaccharide Polymers 0.000 claims description 10
- -1 glucosamine disaccharide Chemical class 0.000 claims description 9
- GZQKNULLWNGMCW-PWQABINMSA-N lipid A (E. coli) Chemical compound O1[C@H](CO)[C@@H](OP(O)(O)=O)[C@H](OC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCCCC)[C@@H](NC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCC)[C@@H]1OC[C@@H]1[C@@H](O)[C@H](OC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](NC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](OP(O)(O)=O)O1 GZQKNULLWNGMCW-PWQABINMSA-N 0.000 claims description 9
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 5
- 229930195729 fatty acid Natural products 0.000 claims description 5
- 239000000194 fatty acid Substances 0.000 claims description 5
- 150000004665 fatty acids Chemical class 0.000 claims description 5
- 239000002253 acid Substances 0.000 claims description 3
- SUHOOTKUPISOBE-UHFFFAOYSA-N O-phosphoethanolamine Chemical group NCCOP(O)(O)=O SUHOOTKUPISOBE-UHFFFAOYSA-N 0.000 claims description 2
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 claims description 2
- 229960002442 glucosamine Drugs 0.000 claims description 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 2
- LFGREXWGYUGZLY-UHFFFAOYSA-N phosphoryl Chemical group [P]=O LFGREXWGYUGZLY-UHFFFAOYSA-N 0.000 claims description 2
- OPTJIKJGOMPIQI-WCTZXXKLSA-N (4R,5R,6R,7R)-1,4,5,6,7,8-hexahydroxyoctan-2-one Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CC(=O)CO OPTJIKJGOMPIQI-WCTZXXKLSA-N 0.000 claims 1
- 125000003277 amino group Chemical group 0.000 claims 1
- 239000001177 diphosphate Substances 0.000 claims 1
- XPPKVPWEQAFLFU-UHFFFAOYSA-J diphosphate(4-) Chemical compound [O-]P([O-])(=O)OP([O-])([O-])=O XPPKVPWEQAFLFU-UHFFFAOYSA-J 0.000 claims 1
- 235000011180 diphosphates Nutrition 0.000 claims 1
- 150000002482 oligosaccharides Polymers 0.000 claims 1
- 238000000034 method Methods 0.000 abstract description 36
- 241000498849 Chlamydiales Species 0.000 abstract description 15
- 230000000405 serological effect Effects 0.000 abstract description 10
- 241001222774 Salmonella enterica subsp. enterica serovar Minnesota Species 0.000 abstract description 9
- 238000003745 diagnosis Methods 0.000 abstract description 9
- 241000293869 Salmonella enterica subsp. enterica serovar Typhimurium Species 0.000 abstract description 8
- 230000001900 immune effect Effects 0.000 abstract description 6
- 238000001514 detection method Methods 0.000 abstract description 4
- 230000035931 haemagglutination Effects 0.000 abstract description 4
- 241000588724 Escherichia coli Species 0.000 abstract description 2
- 241000588770 Proteus mirabilis Species 0.000 abstract description 2
- 238000001962 electrophoresis Methods 0.000 abstract description 2
- 206010061041 Chlamydial infection Diseases 0.000 abstract 2
- 210000002966 serum Anatomy 0.000 description 20
- 241000283973 Oryctolagus cuniculus Species 0.000 description 19
- 239000003513 alkali Substances 0.000 description 9
- 229920001282 polysaccharide Polymers 0.000 description 9
- 239000005017 polysaccharide Substances 0.000 description 9
- 238000012360 testing method Methods 0.000 description 9
- 238000002955 isolation Methods 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- 210000004027 cell Anatomy 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- 241000607142 Salmonella Species 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 230000001580 bacterial effect Effects 0.000 description 6
- 239000000499 gel Substances 0.000 description 6
- 230000003053 immunization Effects 0.000 description 6
- KYQCXUMVJGMDNG-SHUUEZRQSA-N keto-3-deoxy-D-manno-octulosonic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CC(=O)C(O)=O KYQCXUMVJGMDNG-SHUUEZRQSA-N 0.000 description 6
- 208000000143 urethritis Diseases 0.000 description 6
- 230000001154 acute effect Effects 0.000 description 5
- 150000001720 carbohydrates Chemical group 0.000 description 5
- 150000004676 glycans Chemical class 0.000 description 5
- 239000004816 latex Substances 0.000 description 5
- 229920000126 latex Polymers 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- 230000004520 agglutination Effects 0.000 description 4
- 238000003556 assay Methods 0.000 description 4
- 239000012153 distilled water Substances 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 238000002649 immunization Methods 0.000 description 4
- 150000002632 lipids Chemical group 0.000 description 4
- 150000002772 monosaccharides Chemical class 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 229920001817 Agar Polymers 0.000 description 3
- 241000606153 Chlamydia trachomatis Species 0.000 description 3
- 208000029082 Pelvic Inflammatory Disease Diseases 0.000 description 3
- 239000008272 agar Substances 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 229940038705 chlamydia trachomatis Drugs 0.000 description 3
- 230000037029 cross reaction Effects 0.000 description 3
- 238000012258 culturing Methods 0.000 description 3
- 229940009976 deoxycholate Drugs 0.000 description 3
- KXGVEGMKQFWNSR-LLQZFEROSA-N deoxycholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 KXGVEGMKQFWNSR-LLQZFEROSA-N 0.000 description 3
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 235000013601 eggs Nutrition 0.000 description 3
- 210000003743 erythrocyte Anatomy 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 235000015097 nutrients Nutrition 0.000 description 3
- 239000002953 phosphate buffered saline Substances 0.000 description 3
- 241000894007 species Species 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 206010018910 Haemolysis Diseases 0.000 description 2
- 108060003951 Immunoglobulin Proteins 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 241001494479 Pecora Species 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 108010013381 Porins Proteins 0.000 description 2
- 230000000890 antigenic effect Effects 0.000 description 2
- 230000000721 bacterilogical effect Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- 238000012136 culture method Methods 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 230000008588 hemolysis Effects 0.000 description 2
- 150000002386 heptoses Chemical class 0.000 description 2
- 238000000760 immunoelectrophoresis Methods 0.000 description 2
- 238000010166 immunofluorescence Methods 0.000 description 2
- 230000002163 immunogen Effects 0.000 description 2
- 102000018358 immunoglobulin Human genes 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 239000003208 petroleum Substances 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 150000004804 polysaccharides Polymers 0.000 description 2
- 102000007739 porin activity proteins Human genes 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- SQGYOTSLMSWVJD-UHFFFAOYSA-N silver(1+) nitrate Chemical compound [Ag+].[O-]N(=O)=O SQGYOTSLMSWVJD-UHFFFAOYSA-N 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- NNLZBVFSCVTSLA-XMABDTGBSA-N (4r,5r,6r)-6-[(1r)-1,2-dihydroxyethyl]-2,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound OC[C@@H](O)[C@H]1OC(O)(C(O)=O)C[C@@H](O)[C@H]1O NNLZBVFSCVTSLA-XMABDTGBSA-N 0.000 description 1
- MSWZFWKMSRAUBD-IVMDWMLBSA-N 2-amino-2-deoxy-D-glucopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 description 1
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 1
- KYQCXUMVJGMDNG-UHFFFAOYSA-N 4,5,6,7,8-pentahydroxy-2-oxooctanoic acid Chemical compound OCC(O)C(O)C(O)C(O)CC(=O)C(O)=O KYQCXUMVJGMDNG-UHFFFAOYSA-N 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 206010003267 Arthritis reactive Diseases 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- 206010006500 Brucellosis Diseases 0.000 description 1
- 241001647378 Chlamydia psittaci Species 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 241001646716 Escherichia coli K-12 Species 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 102000018713 Histocompatibility Antigens Class II Human genes 0.000 description 1
- 108010027412 Histocompatibility Antigens Class II Proteins 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000219470 Mirabilis Species 0.000 description 1
- 206010029719 Nonspecific reaction Diseases 0.000 description 1
- PLBVFNYORPRCME-YMDUGQBDSA-N OP(O)(O)=O.OC[C@](O)(N)[C@@H](O)[C@H](O)C=O Chemical compound OP(O)(O)=O.OC[C@](O)(N)[C@@H](O)[C@H](O)C=O PLBVFNYORPRCME-YMDUGQBDSA-N 0.000 description 1
- 101710116435 Outer membrane protein Proteins 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 241000588769 Proteus <enterobacteria> Species 0.000 description 1
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 241000473945 Theria <moth genus> Species 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000005875 antibody response Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 239000003613 bile acid Substances 0.000 description 1
- 238000011138 biotechnological process Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- BFMYDTVEBKDAKJ-UHFFFAOYSA-L disodium;(2',7'-dibromo-3',6'-dioxido-3-oxospiro[2-benzofuran-1,9'-xanthene]-4'-yl)mercury;hydrate Chemical compound O.[Na+].[Na+].O1C(=O)C2=CC=CC=C2C21C1=CC(Br)=C([O-])C([Hg])=C1OC1=C2C=C(Br)C([O-])=C1 BFMYDTVEBKDAKJ-UHFFFAOYSA-L 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 229930182830 galactose Natural products 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 210000004408 hybridoma Anatomy 0.000 description 1
- 230000000951 immunodiffusion Effects 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 229940126619 mouse monoclonal antibody Drugs 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 230000002611 ovarian Effects 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 239000013610 patient sample Substances 0.000 description 1
- 210000003800 pharynx Anatomy 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 238000000159 protein binding assay Methods 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 208000002574 reactive arthritis Diseases 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 229910052709 silver Inorganic materials 0.000 description 1
- 239000004332 silver Substances 0.000 description 1
- 229910001961 silver nitrate Inorganic materials 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56911—Bacteria
- G01N33/56927—Chlamydia
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/195—Assays involving biological materials from specific organisms or of a specific nature from bacteria
- G01N2333/295—Assays involving biological materials from specific organisms or of a specific nature from bacteria from Chlamydiales (o)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2400/00—Assays, e.g. immunoassays or enzyme assays, involving carbohydrates
- G01N2400/10—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- G01N2400/50—Lipopolysaccharides; LPS
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S435/00—Chemistry: molecular biology and microbiology
- Y10S435/8215—Microorganisms
- Y10S435/822—Microorganisms using bacteria or actinomycetales
- Y10S435/879—Salmonella
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S436/00—Chemistry: analytical and immunological testing
- Y10S436/811—Test for named disease, body condition or organ function
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S436/00—Chemistry: analytical and immunological testing
- Y10S436/823—Immunogenic carrier or carrier per se
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Molecular Biology (AREA)
- Food Science & Technology (AREA)
- Biochemistry (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Virology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Microbiology (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Compositions Of Macromolecular Compounds (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Priority Applications (11)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FI822348A FI69639C (fi) | 1982-07-02 | 1982-07-02 | Preparat foer anvaendning vid klamydia-diagnostik |
| US06/507,788 US4652518A (en) | 1982-07-02 | 1983-06-24 | Diagnosing chlamydia infections with Re-lipopolysaccharide complexed to carrier or antibody thereto |
| DE8383106453T DE3372018D1 (en) | 1982-07-02 | 1983-07-01 | Preparation for the diagnosis of chlamydial infections and for the production of chlamydial group-specific antibodies |
| JP58118413A JPS5927261A (ja) | 1982-07-02 | 1983-07-01 | クラミジア感染症診断用製剤及びその使用方法 |
| DK304483A DK304483A (da) | 1982-07-02 | 1983-07-01 | Praeparat til anvendelse ved diagnose af infektioner med chlamydia |
| NO832407A NO832407L (no) | 1982-07-02 | 1983-07-01 | Preparat for anvendelse ved diagnose av chlamydiale infeksjoner. |
| EP83106453A EP0098557B1 (de) | 1982-07-02 | 1983-07-01 | Präparat zur Diagnose von Chlamydia-Infektionen und zur Gewinnung der Chlamydiagruppe-spezifischen Antikörper |
| AT83106453T ATE27739T1 (de) | 1982-07-02 | 1983-07-01 | Praeparat zur diagnose von chlamydia-infektionen und zur gewinnung der chlamydiagruppespezifischen antikoerper. |
| DE198383106453T DE98557T1 (de) | 1982-07-02 | 1983-07-01 | Praeparat zur diagnose von chlamydia-infektionen und zur gewinnung der chlamydiagruppe-spezifischen antikoerper. |
| AU16492/83A AU1649283A (en) | 1982-07-02 | 1983-07-01 | Diagnosis of chlamydial infections |
| CA000431720A CA1230551A (en) | 1982-07-02 | 1983-07-04 | Preparation to be used in diagnosis of chlamydial infections |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FI822348A FI69639C (fi) | 1982-07-02 | 1982-07-02 | Preparat foer anvaendning vid klamydia-diagnostik |
| FI822348 | 1982-07-02 |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| FI822348A0 FI822348A0 (fi) | 1982-07-02 |
| FI822348L FI822348L (fi) | 1984-01-03 |
| FI69639B FI69639B (fi) | 1985-11-29 |
| FI69639C true FI69639C (fi) | 1986-03-10 |
Family
ID=8515769
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FI822348A FI69639C (fi) | 1982-07-02 | 1982-07-02 | Preparat foer anvaendning vid klamydia-diagnostik |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US4652518A (de) |
| EP (1) | EP0098557B1 (de) |
| JP (1) | JPS5927261A (de) |
| AT (1) | ATE27739T1 (de) |
| AU (1) | AU1649283A (de) |
| CA (1) | CA1230551A (de) |
| DE (2) | DE98557T1 (de) |
| DK (1) | DK304483A (de) |
| FI (1) | FI69639C (de) |
| NO (1) | NO832407L (de) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4818817A (en) * | 1983-11-30 | 1989-04-04 | Petroleum Fermentations N.V. | Enzymatic degradation of lipopolysaccharide bioemulsifiers |
| CA1212051A (en) * | 1984-03-02 | 1986-09-30 | John W. Cherwonogrodzky | Identification of brucella abortus and brucellosis infection |
| GB8416841D0 (en) * | 1984-07-03 | 1984-08-08 | Technology Licence Co Ltd | Monoclonal antibodies |
| GB8426468D0 (en) * | 1984-10-19 | 1984-11-28 | Technology Licence Co Ltd | Monoclonal antibodies |
| GB8427006D0 (en) * | 1984-10-25 | 1984-11-28 | Iq Bio Ltd | Determination of chlamydia trachomatis |
| US5179001A (en) * | 1985-09-27 | 1993-01-12 | The Regents Of The University Of California | Detection and monitoring of chronic and gram-negative infection |
| US4918163A (en) * | 1985-09-27 | 1990-04-17 | Pfizer Inc. | Monoclonal antibodies specific for lipid-A determinants of gram negative bacteria |
| ES2009365A6 (es) * | 1986-04-24 | 1989-09-16 | Univ California | Procedimiento de otencion de anticuerpos monoclonales para bacterias gram-negativas. |
| CA1336576C (en) * | 1986-09-26 | 1995-08-08 | Malcolm B. Perry | Immunoassays for discriminating between brucellosis infections and vaccinations |
| EP0303515B1 (de) * | 1987-08-13 | 1992-11-11 | Synbiotics Corporation | Bestimmungen einer amphipathischen Substanz durch Verwendung einer lipophilen Oberfläche |
| US4916057A (en) * | 1988-02-29 | 1990-04-10 | Kallestad Diagnostics, Inc. | Chlamydia assay employing base treatment |
| FR2631125A1 (fr) * | 1988-05-06 | 1989-11-10 | Pasteur Institut | Procede de detection directe de chlamydiae, anticorps monoclonaux anti-chlamydiae et leurs applications au diagnostic des infections chlamydiales |
| US5089479A (en) * | 1988-11-28 | 1992-02-18 | Krivan Howard C | Adhesion of mycoplasma pneumoniae and mycoplasma hominus to sulfatide |
| US5484706A (en) * | 1993-05-19 | 1996-01-16 | Pasteur Sanofi Diagnostics | Immunoassay for analytes in samples using alkylating agents |
| AU660268B3 (en) * | 1993-07-16 | 1995-06-15 | Deakin University | Bacteria-specific lipopolysaccharide-like molecules |
| US5773234A (en) * | 1995-08-07 | 1998-06-30 | Quidel Corporation | Method and device for chlamydia detection |
| JPH10339731A (ja) * | 1997-06-06 | 1998-12-22 | Mitsubishi Chem Corp | 腸管出血性大腸菌感染の検出方法 |
| US7220596B2 (en) * | 1998-04-15 | 2007-05-22 | Utah State University | Real time detection of antigens |
| US6399317B1 (en) | 1998-04-15 | 2002-06-04 | Utah State University | Real time detection of antigens |
| CA2664619C (en) * | 2006-10-12 | 2012-12-11 | Glaxosmithkline Biologicals S.A. | Immunogenic compositions comprising an oil-in-water emulsion adjuvant containing a reduced amount of squalene, tocol and an emulsifying agent |
| TW200908994A (en) | 2007-04-20 | 2009-03-01 | Glaxosmithkline Biolog Sa | Vaccine |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4039657A (en) * | 1975-06-19 | 1977-08-02 | Merck & Co., Inc. | Separating antigen from residual common sensitizing protein |
| US4118469A (en) * | 1976-04-27 | 1978-10-03 | Research Corporation | Antigen for trachoma lymphogranuloma venereum (LGV) and non-gonococcal urethritis (NGU) |
| US4096035A (en) * | 1977-06-15 | 1978-06-20 | Merck & Co., Inc. | Separation of trachoma agent from growth medium impurities |
| GB2047889A (en) * | 1979-04-02 | 1980-12-03 | Research Corp | Detection of antibodies to chlormydia trachomatis having an immunofluorescence test |
| EP0017460A1 (de) * | 1979-04-02 | 1980-10-15 | Research Corporation | Immunofluoreszenz-Testmethode und Substanz zur Verwendung darin |
| US4310455A (en) * | 1979-04-17 | 1982-01-12 | Research Corporation | Antigen for early pregnancy test and contraceptive vaccine |
| US4271146A (en) * | 1979-09-06 | 1981-06-02 | Seawell Albert C | Methods of using Chlamydia vaccine for preventing and treating bovine and ovine diseases |
| US4267170A (en) * | 1979-09-06 | 1981-05-12 | Seawell Albert C | Methods of using chlamydia vaccine for preventing and treating bovine diseases |
| BR8108820A (pt) * | 1980-09-24 | 1982-08-24 | Cetus Corp | Processo e sonda de diagnostico |
| US4397959A (en) * | 1980-11-05 | 1983-08-09 | Research Corporation | Forced precipitation method for preparing antigen/antibody particles |
| US4497899A (en) * | 1982-04-12 | 1985-02-05 | Abbott Laboratories | Immunoassay for Chlamydia trachomatis antigens |
-
1982
- 1982-07-02 FI FI822348A patent/FI69639C/fi not_active IP Right Cessation
-
1983
- 1983-06-24 US US06/507,788 patent/US4652518A/en not_active Expired - Fee Related
- 1983-07-01 AU AU16492/83A patent/AU1649283A/en not_active Abandoned
- 1983-07-01 JP JP58118413A patent/JPS5927261A/ja active Granted
- 1983-07-01 DE DE198383106453T patent/DE98557T1/de active Pending
- 1983-07-01 AT AT83106453T patent/ATE27739T1/de not_active IP Right Cessation
- 1983-07-01 DK DK304483A patent/DK304483A/da unknown
- 1983-07-01 EP EP83106453A patent/EP0098557B1/de not_active Expired
- 1983-07-01 NO NO832407A patent/NO832407L/no unknown
- 1983-07-01 DE DE8383106453T patent/DE3372018D1/de not_active Expired
- 1983-07-04 CA CA000431720A patent/CA1230551A/en not_active Expired
Also Published As
| Publication number | Publication date |
|---|---|
| NO832407L (no) | 1984-01-03 |
| DK304483A (da) | 1984-01-03 |
| FI822348A0 (fi) | 1982-07-02 |
| DE3372018D1 (en) | 1987-07-16 |
| US4652518A (en) | 1987-03-24 |
| FI69639B (fi) | 1985-11-29 |
| EP0098557B1 (de) | 1987-06-10 |
| JPS5927261A (ja) | 1984-02-13 |
| FI822348L (fi) | 1984-01-03 |
| JPH0450531B2 (de) | 1992-08-14 |
| DK304483D0 (da) | 1983-07-01 |
| DE98557T1 (de) | 1984-07-05 |
| EP0098557A3 (en) | 1984-04-04 |
| CA1230551A (en) | 1987-12-22 |
| ATE27739T1 (de) | 1987-06-15 |
| AU1649283A (en) | 1984-01-05 |
| EP0098557A2 (de) | 1984-01-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FI69639C (fi) | Preparat foer anvaendning vid klamydia-diagnostik | |
| Brade et al. | Chemical, biological, and immunochemical properties of the Chlamydia psittaci lipopolysaccharide | |
| Pollack et al. | Specificity and cross-reactivity of monoclonal antibodies reactive with the core and lipid A regions of bacterial lipopolysaccharide | |
| US4683196A (en) | Method and materials for the identification of lipopolysaccharide producing microorganisms | |
| Mandrell | Further antigenic similarities of Neisseria gonorrhoeae lipooligosaccharides and human glycosphingolipids | |
| Gulati et al. | Immunogenicity of Neisseria gonorrhoeae lipooligosaccharide epitope 2C7, widely expressed in vivo with no immunochemical similarity to human glycosphingolipids | |
| JPS61500355A (ja) | グラム陰性菌のエンドトキシンに対するモノクロナ−ル抗体 | |
| Nurminen et al. | Immunologically related ketodeoxyoctonate-containing structures in Chlamydia trachomatis, Re mutants of Salmonella species, and Acinetobacter calcoaceticus var. anitratus | |
| Peterson et al. | Characterization of a neutralizing monoclonal antibody directed at the lipopolysaccharide of Chlamydia pneumoniae | |
| Chart | Lipopolysaccharide: Isolation and characterization | |
| Tsang et al. | A murine monoclonal antibody specific for the outer core oligosaccharide of Salmonella lipopolysaccharide | |
| Sylvester et al. | Burkholderia (basonym Pseudomonas) cepacia binding to lipid receptors | |
| Nalbantsoy et al. | Isolation and purification of O and H antigens from Salmonella Enteritidis as diagnostic tool | |
| McCALLUS et al. | Antibody specific for Escherichia coli J5 cross-reacts to various degrees with an Escherichia coli clinical isolate grown for different lengths of time | |
| WO1985002685A1 (en) | Method and materials for the identification of lipopolysaccharide producing microorganisms | |
| Young et al. | “Core” glycolipid of Enterobacteriaceae: immunofluorescent detection of antigen and antibody | |
| Pekkola‐Heino et al. | Monoclonal antibodies reacting selectively with core and O‐polysaccharide of Yersinia enterocolitica O: 3 lipopolysaccharide | |
| Craven et al. | Natural bactericidal activity of human serum against Neisseria meningitidis isolates of different serogroups and serotypes | |
| Yamada et al. | Serodiagnosis by passive hemagglutination test and verotoxin enzyme-linked immunosorbent assay of toxin-producing Escherichia coli infections in patients with hemolytic-uremic syndrome | |
| Brade et al. | Specificity of monoclonal antibodies against Escherichia coli K-12 lipopolysaccharide | |
| de Hormaeche et al. | Definition of a virulence-related antigen of Neisseria gonorrhoeae with monoclonal antibodies and lectins | |
| Andersen et al. | Cross-reactive polyclonal antibodies to the inner core of lipopolysaccharide from Neisseria meningitidis | |
| Kaca et al. | Complement activation by Proteus mirabilis negatively charged lipopolysaccharides | |
| CA1214101A (en) | Preparation to be used in diagnosis of chlamydial infections | |
| EP0918796B1 (de) | Monoklonaler antikörper für die agglutinierung von e. coli, das ein protein der cs4/cfa-familie enthält |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM | Patent lapsed |
Owner name: ORION-YHTYMAE OY |